Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a Phase 1 study in stem cell mobilization, with the results expected by the end of 2014 or early 2015.